Martingale Asset Management L P Sells 1,300 Shares of ChemoCentryx, Inc. (NASDAQ:CCXI)
Martingale Asset Management L P Sells 1,300 Shares of ChemoCentryx, Inc. (NASDAQ:CCXI)
Martingale Asset Management L P trimmed its holdings in ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) by 7.4% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 16,334 shares of the biopharmaceutical company's stock after selling 1,300 shares during the quarter. Martingale Asset Management L P's holdings in ChemoCentryx were worth $410,000 at the end of the most recent reporting period.
根据最近提交给美国证券交易委员会的文件，Martingale Asset Management LP在第一季度将其在ChemoCentryx，Inc.(纳斯达克代码：CCXI-GET Rating)的持股削减了7.4%。该机构投资者在本季度出售了1,300股后，持有这家生物制药公司的16,334股票。在最近一个报告期结束时，Martingale Asset Management L P在ChemoCentryx持有的股份价值410,000美元。
A number of other hedge funds have also bought and sold shares of CCXI. UMB Bank N A MO purchased a new stake in shares of ChemoCentryx during the 4th quarter valued at about $37,000. Lazard Asset Management LLC bought a new stake in ChemoCentryx in the 4th quarter worth approximately $60,000. Prospera Financial Services Inc bought a new stake in ChemoCentryx in the 1st quarter worth approximately $46,000. Point72 Hong Kong Ltd purchased a new stake in ChemoCentryx during the 4th quarter valued at $115,000. Finally, Commerce Bank bought a new position in shares of ChemoCentryx during the 4th quarter valued at $219,000. Hedge funds and other institutional investors own 81.09% of the company's stock.
其他一些对冲基金也买卖了CCXI的股票。UMB Bank N A MO在第四季度购买了ChemoCentryx的新股份，价值约3.7万美元。Lazard Asset Management LLC在第四季度购买了ChemoCentryx的新股份，价值约6万美元。普罗斯佩拉金融服务公司在第一季度购买了ChemoCentryx的新股份，价值约4.6万美元。Point72 Hong Kong Ltd在第四季度购买了ChemoCentryx的新股份，价值11.5万美元。最后，商业银行在第四季度购买了价值21.9万美元的ChemoCentryx股票的新头寸。对冲基金和其他机构投资者持有该公司81.09%的股票。
Insider Activity
内幕活动
In related news, Director James L. Tyree sold 3,863 shares of the company's stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $25.66, for a total value of $99,124.58. Following the completion of the transaction, the director now owns 19,138 shares of the company's stock, valued at approximately $491,081.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director James L. Tyree sold 3,863 shares of the business's stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $25.66, for a total value of $99,124.58. Following the transaction, the director now directly owns 19,138 shares in the company, valued at $491,081.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas J. Schall sold 130,000 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $50.24, for a total value of $6,531,200.00. Following the sale, the chief executive officer now owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The disclosure for this sale can be found here. Insiders have sold 217,623 shares of company stock worth $10,848,962 in the last three months. Company insiders own 8.30% of the company's stock.
在相关新闻中，董事詹姆斯·L·泰里在6月9日星期四的一次交易中出售了3,863股该公司股票。这些股票的平均价格为25.66美元，总价值为99,124.58美元。交易完成后，董事现在拥有19,138股该公司股票，价值约491,081.08美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过以下链接获得。其他新闻方面，董事詹姆斯·L·泰里在一笔日期为6月9日(星期四)的交易中出售了3,863股该公司股票。这只股票的平均售价为25.66美元，总价值为99,124.58美元。交易完成后，董事现在直接拥有该公司19,138股，价值491,081.08美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的，可以通过这个超级链接获得。此外，首席执行官托马斯·J·沙尔在8月4日(星期四)的交易中出售了13万股该公司股票。这只股票的平均售价为50.24美元，总价值为6,531,200.00美元。出售后，首席执行官现在拥有2393,352股公司股票，价值约120,242,004.48美元。此次拍卖的披露信息可在此处找到。在过去的三个月里，内部人士已经出售了217,623股公司股票，价值10,848,962美元。公司内部人士持有该公司8.30%的股份。
ChemoCentryx Price Performance
ChemoCentryx性价比
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several analysts recently commented on CCXI shares. SVB Leerink lowered ChemoCentryx from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $64.00 to $52.00 in a report on Friday, August 5th. StockNews.com upgraded shares of ChemoCentryx from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. Stifel Nicolaus downgraded shares of ChemoCentryx from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 target price for the company. in a report on Friday, August 5th. Finally, HC Wainwright cut shares of ChemoCentryx from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $101.00 to $52.00 in a research note on Friday, August 5th. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ChemoCentryx currently has a consensus rating of "Hold" and a consensus price target of $65.25.
几位分析师最近对CCXI的股票发表了评论。SVB Leerink在8月5日星期五的一份报告中将ChemoCentryx的评级从“跑赢大盘”下调至“市场表现”，并将该股的目标价从64.00美元下调至52.00美元。在8月10日星期三的一份研究报告中，股票新闻网站将ChemoCentryx的股票评级从“卖出”上调为“持有”。Stifel Nicolaus在8月10日星期三的一份报告中将ChemoCentryx的股票评级从买入下调至持有。Canaccel Genuity Group将ChemoCentryx的股票评级从买入下调至持有，并为该公司设定了52.00美元的目标价。在8月5日星期五的一份报告中。最后，在周五的一份研究报告中，HC Wainwright将ChemoCentryx的股票评级从买入下调至中性，并将该股的目标价从101.00美元下调至52美元。六位投资分析师对该股的评级为持有，两位给予买入评级，一位给予该公司强烈的买入评级。根据MarketBeat.com的数据，ChemoCentryx目前的共识评级为持有，共识目标价为65.25美元。
About ChemoCentryx
关于ChemoCentryx
(Get Rating)
(获取评级)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
ChemoCentryx，Inc.是一家生物制药公司，专注于在美国开发和商业化治疗炎症性疾病、自身免疫性疾病和癌症的新药。它提供TAVNEOS(Avacopan)，一种口服的选择性C5aR抑制剂，用于治疗严重的抗中性粒细胞胞浆自身抗体相关性小血管炎的成人患者。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- MarketBeat Podcast: Stock Market, Bad News is Good News
- Forget Bitcoin, Block's Ecosystems are the Real Growth Drivers
- What Does an Inverted Yield Curve Mean For You?
- SPY vs. QQQ: Which ETF Wins in 2022?
- Could Snap Stock Rebound As Management Restructures?
- 免费获取StockNews.com关于ChemoCentryx(CCXI)的研究报告
- 市场Beat播客：股市，坏消息就是好消息
- 忘掉比特币吧，Block的生态系统才是真正的增长动力
- 收益率曲线倒置对你意味着什么？
- 标普500ETF VS QQQ：2022年哪只ETF胜出？
- 随着管理层重组，股市能否迅速反弹？
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating).
想看看还有哪些对冲基金持有CCXI吗？访问HoldingsChannel.com获取ChemoCentryx，Inc.(纳斯达克代码：CCXI-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChemoCentryx日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChemoCentryx和相关公司的最新新闻和分析师评级的每日简要摘要。